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Abstract
Breast cancer is one of the most common in female population worldwide and comprises 
about 22.9% of all cancers. Despite the prognosis and survival rates of breast cancer 
patients and survivors are comparatively better than other cancers, but their net outcome 
can be revealed by other factors like tumor grade, secondary effects of chemotherapy like 
insomnia and health behaviors, this distressing may decrease patient’s life expectancy. 
In the backdrop of this, the need of the hour for the breast cancer survivors is to assess 
multifactoral nonpharmacological interventions and the management that includes 
physical exercise, psychological and complementary medicine, which could be cost effec-
tive, widely accessible and more promising for breast cancer patients and survivors apart 
from pharmacological interventions.
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1. Introduction
Breast cancer is the most common noncutaneous form of cancer and principal cause of cancer 
related deaths among females worldwide [1, 2]. Globally with an estimation of more than 1.38 
million new cases (around 23%), the breast cancer ranks second (10.9%) among all cancers [1, 3]. 
In 2017, approximately 252,710 women and 2470 men cases were diagnosed with breast can-
cer. Approximately around 40,610 women and 460 men were expected to die from breast 
cancer in 2017 [4]. The survival rates and prognosis for breast cancer are mostly dependent 
on the type of cancer, stages, treatment, and the ethnicity and location of the patient. High 
survival rates have been observed in breast cancer cases of western world as compared to 
developing countries where survival rates are less. More than 3.5 million women with a 
breast cancer are still alive in the United States and are either having cancer or undergoing 
© 2018 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
treatment [4, 5]. The incidence rates of breast cancer vary from 19.3 per 100,000 women in 
Africa to 89.7/100,000 women in Europe [6]. The highest incidence (≥80/100,000) in devel-
oped parts of the world (excluding Japan) and the lowest incidence (≤40/100,000) in most of 
the developing part the world [7, 9]. There are a number of factors responsible for causing 
breast cancer. Dietary factors, such as high-fat diet, alcohol intake, smoking, obesity, higher 
levels of cholesterol, and iodine deficiency have high risk of cancer occurrence. Due to the 
highest incidence of breast cancer in USA, Australia, New Zealand and UK, makes them top 
priority countries for breast cancer awareness [8, 9]. It is well documented that breast cancer 
is strongly related to age; only 5% of all breast cancers occur in women are less than 40 years 
of age and more than 80% of all female breast cancers arise among women aged 50 or more 
years [10]. In general the age of a woman is directly correlated with higher risk of developing 
breast cancer. The majority of breast cancers are not hereditary [11]. In about <5% of cases, 
breast-ovarian cancer syndrome occurs by inheritance including women having BRCA1 and 
BRCA2 mutation. The 90% of total genetics account to these mutations with a breast cancer 
risk of 60–80% affected cases. BRCA1 mutations predispose women to breast and ovarian 
cancers. BRCA1 in breast cancer has higher aneuploidy number than tumors, which do not 
have mutations in BRCA1. About 85% of breast cancers occur in women who have no family 
history of breast cancer [12].
From the recent past improved therapeutics have greatly increased the chance of survival. 
The median age at diagnosis of breast cancer is 61 years, whereas 43% are older than 
65 years at diagnosis; therefore, cancer survivorship should be conduct in coordination 
with comorbidities related with aging [10, 12]. Around 61% will have confined disease, for 
which survival success are highest (5-year relative survival rates: 99% for localized-stage 
breast cancer vs. 25% for distant-stage breast cancer [13]. Long-term survival is common 
after breast cancer therapeutics, in the midst of a 5-year survival rate of approximately 
90%; hence, addressing survivors’ exclusive post-treatment requires decisive to providing 
quality health care [14].
The National Coalition for Cancer Survivorship and NIH defines individuals as survivors 
from the time of their diagnosis through the balance of their lives [15]. Owing to enhancement 
in cancer care, as well as earlier detection and improved therapeutics, the cancer survivors in 
the USA has been gradually mounting over the last 30 years (~12 million in 2007) and is likely 
to keep on to increase [16]. Cancer survivors also survive longer following cancer diagnosis 
(~5 million survive more than 10 years) and two-thirds are aged 65 years and above [17]. 
However, improved survival brings numerous challenges that varies from an high risk for 
cancer recurrence and the advanced development of second or other new primary cancers, 
to a host of chronic circumstances (e.g., osteoporosis, thromboembolic disease, and cognitive 
impairment, cardiovascular disease), and plethora of inconvenient physical and emotional 
symptoms [18]. Recent studies document that underlying pathophysiological changes in 
survivors’ metabolic, immune, central nervous systems, and neuroendocrine including the 
sleep-wake cycle, contribute to these manifestations is emerging features in clinical practice is 
important for many reasons. First, breast cancer survivors make use of extra care during their 
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first 5 years after diagnosis than their age-matched controls, yet time and again report that 
their needs have not been met [19]. Second, poorly controlled features may lead to decreased 
adherence to adjuvant endocrine therapy [20]. Indeed, many reports document that only 
50% adherence to completion of 5-year adjuvant endocrine therapeutic regimens, leading to 
poorer survival [21]. Third, although majority of the breast cancer survivors account compa-
rable quality of life (QoL) with respect to age-matched controls and experience post-traumatic 
development after cancer, for a subset of survivors, physical and emotional features can upset 
their QoL [22].
Breast cancer survivors’ success not only depends on their prognosis, but also on a host of 
other characteristics, including undesirable effects of cancer therapeutics, available to and 
accessibility of survivorship care, economic, social, medical care and cultural variables, 
QoL and health behaviors [23]. Considerable numbers of breast cancer survivors do not 
stick to approved health maintenance attract toward good health behaviors, such as avoid 
or low alcohol intake, cessation of smoking, maintaining good health and body weight and 
maintaining habit of physical activity, can drastically diminish survivors’ risk of breast 
cancer recurrence [23]. However, benefits may be hampered by cancer-and therapeutics-
associated morbidity, particularly, if the clinical features are causal to morbidity are not 
well regulated [24]. Therefore, of these improvement in cancer survivorship, many organi-
zations for instance the US CDC have called for “public and medical health professionals 
to: (a) addressing the potential long-term and overdue effects of cancer and associated 
therapeutics on survivors’ physical and psychosocial health, (b) offer survivors by means 
of harmonized care to deal with their several symptoms, and (c) foster the significance of 
healthy behaviors (e.g., cessation of smoking and physical exercise) to diminish the risk 
for new type or recurrent cancer and early detection to augment the chances of survival 
with new or recurrent cancer [2, 3]. QoL of enduring cancer survivors has been planned 
to be constituted of four principal domains of health: social, psychological, and spiritual 
physical. Given a number of inclusive overviews of the whole scenario of breast cancer 
survivorship QoL, we wanted to present an upgrade of the most recently published lit-
erature. Therefore, our focal point in this book chapter is to emphasize updated work in 
the field, of breast cancer survivorship and management, prioritizing from last few years 
of research, with intent of providing clinicians the realistic suggestion to enlighten their 
practices [25, 26].
2. Role of primary care providers (PCPs) in breast cancer survivors
Depending on number of survivor’s, primary care physicians should have access to the 
evidence and be able to provide care and follow up. Breast cancer prevalence rates are 
alarming due to the growth and aging of the population [27]. Women are able to sur-
vive with breast cancer after treatment that follows up routinely to detect any recurrence 
and manage late and long-term outcomes of treatment [28]. Breast cancer survivors are 
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growing in number with increase in cost for their well-being, follow up and other medical 
care facilities [29]. The role of primary care providers is increasingly being taken up for 
follow-up care and same should be maintained as we have limited secondary care facilities 
[30]. There should be a systematic registry and data maintenance that follow up is being 
done and breast cancer survivors are effectively treated in primary care [3]. There is a 
short and long term side effect on health of breast cancer survivors including physical, 
emotional, sexual and social consequences such as pain, depression, fatigue, weakness 
[31]. The loss of confidence in leading a normal life is one of the increasing factors which is 
treated by primary care system and are involved more as compared to control patients [32]. 
It is important that PCPs should provide good and maximum care to cancer survivors and 
need of patient’s should be satisfied. PCPs prefer to guide on disease recurrence and risk 
management involved in cancer treatment and survival of patient [32]. The evidence based 
recommendations are provided to PCPs for cancer survivors and are available for clini-
cal practice guidelines [32]. Most of the recommendation is available on how recurrences 
occurs in a breast cancer patient and are concerned with diagnosis [3, 33]. Mammography 
has been recommended to breast cancer patients on follow-up in five guidelines and physi-
cal examination of breast in three of them [3, 33]. Ultrasound is recommended in one of 
the guideline while undergoing mammography [33]. All these guidelines advise genetic 
counseling for risk factors and patients are educated enough to know about signs and 
symptoms of recurrence or any other underlying cause and sign, how to resolve it and 
inform your medical advisor [3, 33].
3. Management strategies for breast cancer
Despite the prolonged survival and improved lifespan, there are a few manifestations 
that breast cancer survivors’ physical utility might diminish more rapidly than that of 
their peers. These survivors might facilitate from an approach that is frequently applied 
in the aging population [34]. First, survivors encounters several, congregate and chronic 
features. Second, survivors display psychological, physical, and behavioral variations that 
may hamper their efficient status and lead to dependence and impairment, as revealed 
by higher fall risk, reduced physical exercise and distinguishes limitations in both basic 
and highly developed activities of daily living [3]. Thus, a subset of characteristic breast 
cancer survivors set to benefit from a management approach that is regularly applied in 
the elderly medicine situations, one that is: multidisciplinary (e.g., behavioral and physi-
cal factors); multifactorial (i.e., one intervention targets multiple symptoms simultane-
ously); augmented use of nonpharmacological treatment intervention options; and setting 
therapeutic goals (i.e., recognizing that complete resolution may not be achieved, but 
improvement is likely) [35] (Table 1). Various pharmacological and nonpharmacological 
interventions are used for the therapeutics of breast cancer as well as post therapeutics are 
shown in Figure 1. In a below section, we will demonstrate this concept by stressing basic 
measurement and management principles that apply evenly across numerous frequently 
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observed physical and emotional features in breast cancer survivors, such as adjustment 
disorder, cognitive dysfunction, or other vasomotor symptoms, psychosocial distress, and 
fatigue and insomnia.
Treatment type Long-term shortcomings Late shortcomings
Surgery Loss of dermal sensation. Body shape 
change. Sexual disturbance. Impaired 
movement. Motion poor weakness
Lymphedema
Neurological disorder
Radiation therapy to the 
breast including chest 
adjacent wall lymphatic 
nodes
Weakness
Skin is sensitive to pain
Impaired pain
Pain
Pneumonitis
Poor dressing sense
Breast atrophy
Lymphedema
Impaired pain or weakness of the 
upper limb
Skin color change
Asymmetric breast
Sexual disturbance
Ataxia telangiectasia-
Neural dysfunction lymphedema
Breast volume not same in both affected and 
normal
Difficulty in breath fibrosis
Cardiovascular disease
Second primary cancers arise of soft-tissue 
thorax, cervical, shoulder, lung cancer
Chemotherapy Sexual disturbance fertility decreased 
Gain of body weight and mass, fat 
accumulation increases, neurological 
disorders, weight gain, oral, hair loss
Weakness
Ovarian dysfunction
Osteoporosis/osteopenia
Cardiovascular risk factors at increased level 
increased risk of (cardiomyopathy, congestive 
heart failure) with chemotherapy
Leukemic malignancies at increased risk 
with alkylating agents, anthracyclines, other 
topoisomerase II inhibitors
Hormonal therapy
Tamoxifen Hot flashes, menstrual cycle irregular, 
mood swings
Increased triglycerides
Increased cardiovascular diseases, cervical 
cancer, blood clotting, bone malformation in 
premenopausal women
Aromatase inhibitors Vaginal dryness, sexual dysfunction, 
muscle pain, neurological disorder, 
cholesterol increased
Osteoporosis, bone malformation, bone 
fracture
Targeted therapy
Trastuzumab Cardiac arrest, cardiac dysfunction
Psychosocial long-term  
and late shortcomings
Mental depression, tension, headache, unpleasant behavior, social distress, physically 
un well, pain, end of life bad dreams, death fear, social difficulties, sexual problems, 
relations problems, financial shortcomings
Table 1. Long term and short term short comings of breast cancer therapeutic interventions.
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4. Surgical treatment of breast cancer
Primary management of breast cancer is surgery. Most of the women diagnosed with early breast 
cancer underwent surgery. It may be wide local excision or mastectomy. Mastectomy is indicated 
when there is a presence of polycentric invasive cancer spots, inflammatory carcinoma, intra-
ductal carcinomas, large primary tumors and patient preference [36]. Skin-sparing mastectomies 
followed by immediate reconstruction are now one of the most popular forms of reconstruction 
[36]. The status of the axillary lymph nodes is an important prognostic factor in early stages 
of breast cancer. During the operation, the lymph nodes in the axilla are also considered for 
removal. Axillary lymph node dissection remains the standard of care for patients with clinically 
palpable or positive histological confirmed lymph nodes [36]. Sentinel lymph node biopsy(SLNB) 
is an advanced technique and is very helpful in the management of axilla [37]. SLNB technique 
is based on the observations that tumor cells migrate from the primary cancer site to one of the 
nearby lymph nodes before moving to other distant lymph nodes [38]. In patients with a negative 
Figure 1. Different therapeutic targets in breast cancer treatment explain role of each new agent, its benefit to survivors.
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lymph node biopsy, there is no requirement of axillary lymph node dissection (ALND) [39]. This 
in turn reduces the risk of lymphedema and other complications such as nerve injury and mus-
cular problems, associated with the axillary lymph node dissection surgery [40].
5. Pharmacological interventions
5.1. Adjuvant chemotherapy for breast cancer management
Some patients with early breast cancer relapse with stage IV breast cancer even after surgery, 
reason may be the presence of micrometastatic disease present before the surgery [2]. For this 
reason in breast cancer patients adjuvant systemic therapy are used to halt the process of can-
cer recurrence [2]. It has been shown and proved by several trials that 6 months anthracycline 
therapy following surgical treatment of cancer results in about 40% reduction in mortality 
rates from breast cancer in women below age of 50 years and 20% reduction in between 56 and 
69 age group [2, 41]. Further analysis showed that the addition of taxane based chemotherapy 
to anthracycline based regimen reduced mortality rate by further 15% [2, 41].
5.2. Adjuvant trastuzumab monoclonal antibody
At least 18–20% of breast cancer patients tumor cells overexpress HER-2 proteins [42]. In 
these patients trastuzumab (monoclonal antibody) is given as an adjuvant therapy [2, 42]. 
Full course of 52 treatments are given to woman with breast cancer [42]. Trastuzumab is well 
tolerated at therapeutic doses but may result in cardiac toxicity in patients initially given 
anthracycline regimen or in patients having baseline cardiac problem [43]. Left ventricular 
dysfunction and heart failure is reported in some patients by administration of trastuzumab 
[42]. All breast cancer patients should have scheduled cardiac monitoring before and during 
administration of therapy [2, 42].
5.3. Adjuvant endocrine therapy and breast cancer management
The majority of breast cancers are estrogen receptor (ER) positive [2, 42]. In those women with 
ER positive breast cancer, adjuvant endocrine therapy is routinely offered [2, 42]. The addi-
tion of endocrine therapy following either adjuvant chemotherapy or radiotherapy confers a 
further reduction in mortality rates [2, 42]. Tamoxifen is the mainstay of endocrine treatment 
in premenopausal woman [2, 42]. In post-menopausal woman aromatase inhibitors are the 
agents of choice [2, 42].
6. Non-pharmacological interventions
6.1. Psychophysiological symptoms
A thorough approach to evaluate the symptom management is to investigate in detail whether 
symptoms can be accredited to cancer and associated therapeutics and other procedures 
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including anesthesia or to additional contributing factors that are capable to be reversible 
[44]. These various factors might include anemia, vitamin deficiencies, organ dysfunction, 
metabolic, intracranial or endocrine abnormalities. The suitable investigations for various 
deficiencies can be assessed by methods which include imaging studies, blood work and/
or neuropsychological testing. Additionally, the sensible and careful listening to survivors, 
education and multifactorial assistance from other disciplines (e.g., physical and behavioral 
medicine) associated to survivors may contribute to therapeutics significantly [45].
Management comprises of pharmacological therapeutic intervention (e.g., antidepressants or 
stimulants) in combination with a range of nonpharmacological interventions, for example 
psychological support, physical therapy, complementary medicine and nutritional counseling 
[46, 47]. The other choice to pharmacological therapeutic intervention for managing these side 
effects is psychological therapeutic interventions [48, 49]. Various behavioral interventions 
are linked with the diathesis stress model. This model explains how acute symptoms might 
develop into well-established or long lasting. However, many patients have predisposing fac-
tors to make them more susceptible to the event of insomnia. Such as, under the precipitating 
factor like stress, biologically older female patients sleep very less and make them prompt for 
low threshold for developing insomnia [50]. Owing to the cancer diagnosis and its therapeu-
tics, undoubtedly accumulates more stress and advance in the development of acute insomnia. 
In an effort to mitigate their symptoms, patients may draw in behaviors that eventually per-
petuate their insomnia. Cognitive Behavioral Therapy for Insomnia (CBT-I) proposed by Spiel 
man provide the foundation of this model [25]. For instance a patient may initiate to spend 
more time in bed or take more naps throughout the day in the hopes that this would lessen 
her tiredness or fatigue, when in fact it may intensify his/her insomnia by disturbing the sleep 
wake and circadian cycles [51]. A behavioral therapeutic intervention aims these perpetuating 
behaviors to decrease sleeplessness problems and assist patients develop a more regular and 
standard sleep schedule. A behavioral therapist would support the patient to circumvent com-
pensatory methods, such as sleeping during the course of day or lounging in bed, or would 
initiate stimulus control methods, such as reserving bed for sleep and sex only to decrease the 
number of relations with bed that are not conducive for sleep (watching TV, worrying, stay-
ing awake). Some of these therapies influence multiple symptoms, which is the need of hour 
[1]. For example, increasing physical exercises not only develops functional status, strength 
and survival, but also facilitates improved QoL, emotional, cognitive and physical symptoms 
and on the whole cancer-associated mortality [52]. A sensible and well knowledgeable dis-
cussion can assist to delineate an individualized management approach that accounts for 
aforementioned therapeutics, patient preferences and insurance coverage. Pursuing nonphar-
macological treatment management can be formidable, as it frequently entails more dynamic 
involvement of the survivor (e.g., time and expense). For example, cancer survivors might be 
challenged in their pursuit to commence, continue or enhance the height of physical exercise 
by logistical difficulties, attained physical constraints or a fear of injury. In these occasions, 
a proficient cancer exercise trainer or a physical therapist is an important resource. Cancer 
survivors may undergo discouraged when misery with long lasting symptoms, and even 
though most breast cancer survivors manage well, some survivors become significantly laden 
by symptoms, and in this case, a brief course of psychological therapy focused on empower-
ment, increased self-care and coping skills may prove helpful [53, 54].
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6.2. Physical activity
Physical exercise has been proved to have potential to counter numerous cancer-associated 
therapeutic side effects. Scientific world has documented that proper physical exercise 
strongly related with improved outcomes. Various reports and meta-analysis revealed that 
proper and well managed physical exercise have many health benefits and could amelio-
rate anxiety, improved quality of life such as blood circulation, physical fitness, depression, 
improving body shape, remove depression, good impact on quality of life, cognitive impair-
ment and decreases inflammation as well as diminishes toxicities stemming from deleterious 
cancer therapeutics [55]. Breast cancer survivors should be recommended to revisit to normal 
daily activities as quickly as possible after diagnosis and to continue engaging in regular 
physical activity [3, 55]. The guidelines recommended for cancer patients and cancer survivors 
reported in American College of Sports Medicine documents that one should perform moder-
ate intensity aerobic activity includes gardening, walking and ballroom dancing for 150 min 
or strenuous aerobic exercise which includes jogging, race walking or hiking uphill for 75 min 
in a week and 20–30 min of moderate-intensity anaerobic muscle strengthening activity for 
at least twice a week [2, 3, 55]. Additional details about the amount of time required for each 
entire training session is less clear. More importantly cancer patient and survivor should 
inquire about the advice of oncologist and/or primary care clinician prior to initiate a new 
activity. However working with professional trainers who are skilled to perform such type 
of exercise for cancer patients and survivors, and acquire individualized exercise directions 
that account for different types of cancer, disease progression, comorbidities, physical limita-
tions, age, and other appropriate factors [3]. Additionally preliminary reports document the 
fact that proper regular exercise from well trained person could confer a survival benefit and 
is related with or increase overall quality of life significantly across the cancer patients and 
cancer survivors. It is worth to mention that up to 70% of breast cancer survivors do not 
meet these ACSM public health recommendations and have not taken any opinion to discuss 
activity with respective oncology care team [56]. About 32% of cancer survivors meet the 
recommendations for physical activity. Observational evidence advocates greater amounts of 
physical exercise may be needed, even though the data is insufficient to make it an approval 
at this time; aerobic exercise of 3 h or more per week may possibly be needed to improve 
breast cancer survival [57]. However, reports revealed that cancer survivors of entire ages 
would like their oncologist to start discussion about activity and formulate suitable referrals 
timely in the therapeutic course [57]. Given the benefits of physical activity during and after 
the cancer therapeutics, schedule discussions about exercise between the oncologist team and 
cancer patients and survivors in combination with referrals to a trainer exercise physiologist 
could considerably advance cancer therapy adherence, side effect burden, recovery, quality of 
life, as well as disease-free and overall survival in breast cancer patients and survivors [3, 57].
6.3. Nutrition
The diet characterized by high content of vegetables, fruits, whole grains, and legumes (vs a 
typical Western diet) has been related with a low risk (range, 15–43%) in all-cause mortality. 
Only 18–34% of breast cancer survivors report eating five or more fruit and vegetables daily 
[58]. Data from the two large RCTs of diet therapy in breast cancer survivors and patients 
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suggest that the dietary change adequately result in weight loss and may possibly be required 
to favorably impact breast cancer recurrence and prognosis [3]. As per ACS nutrition and 
physical activity guidelines, alcohol consumption should be limited to no more than one drink 
per day for women, as in the general population [3]. Data are not consistent but advocate that 
breast cancer survivors who consume more than three to four drinks per week are at high 
risk for breast cancer recurrence. Various studies revealed that the carcinogenic ingredient of 
alcohol consumption augments the risk of developing numerous types of cancers irrespective 
of the type (i.e., wine, beer, etc.), and recommended limits [3]. About 7% of breast cancer 
survivors revealed the excessive drinking of alcohol. Based on these facts, survivors should 
be counseled to: achieve a dietary pattern that is high in vegetables, fruits, whole grains, and 
legumes; limit alcohol intake to no more than one drink per day; and follow the ACS guide-
lines on nutrition and physical activity for cancer survivors with intend on successful weight 
management [3, 59].
6.4. Musculoskeletal symptoms
Despite other deleterious effects, breast cancer survivors may account intricacies with 
the ipsilateral upper end after surgery, as well as decreased range of motion, rotator cuff 
injury, adhesive capsulitis (“frozen shoulder” with firmness and pain in the shoulder joint), 
and axillary web syndrome (“cording” in the skin of the inner arm with ambiance of pain 
and stiffness that emerge as a web or a corded rope) [3]. These malformations can lead to 
a decline capability to perform exercise of daily living and can effect employment [1, 3]. 
Other therapies like systemic therapy may also be associated with the progression of mus-
culoskeletal symptoms in breast cancer survivors [1, 3]. Musculoskeletal symptoms are very 
common in the midst of breast cancer survivors, whether due to aromatase inhibitor therapy, 
menopause or chemotherapy, The incidence of musculoskeletal symptoms in breast can-
cer patients differs significantly: these include restricted shoulder range of motion (range, 
1.5–50% of patients), musculoskeletal pain (range, 12–51% of patients), upper limb tiredness 
(range, 18–23% of patients), and immobility or numbness (range, 29–81% of patients). Above 
50% of breast cancer survivors endure a musculoskeletal syndrome on initiation of an aro-
matase inhibitor, generally as either new or worsened diffuse arthralgias or myalgias, which 
most often develop within 2–3 months. Around 30% of breast cancer survivors entail to stop 
early adjuvant aromatase inhibitor therapy due to deleterious effects (~25% because of mus-
culoskeletal symptoms) [1, 3, 60, 61]. In particular, up to 50% of postmenopausal women 
undergo therapeutics with aromatase inhibitor medications report arthralgias (joint pain) 
and myalgias (muscle pain) that are intense enough in 20% of women to lead to therapeutics 
discontinuation [1, 61]. These aromatase inhibitor-related musculoskeletal symptoms are 
frequently not receptive to nonsteroidal anti-inflammatory drugs or acetaminophen [1, 61]. 
Another option for treatment is alternative therapy that is replacement of one antiestrogen 
therapy with another. More than 40% of the patients who discontinue the drug may toler-
ate a distinct aromatase inhibitor or a discrete formulation of the aromatase inhibitor. The 
rest usually tolerate tamoxifen. Poor compliance/adherence to therapeutics has revealed the 
high risk of breast cancer recurrence, therefore serving breast cancer patients and survivors 
management and their symptoms and supporting drug compliance has utmost importance 
[1, 61]. Albeit a underlying relationship is possibly to be due to cancer therapeutics or 
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menopausal transition, new diagnostics, such as autoimmune or crystalline arthritis, should 
not be ignored. Treatment modalities are similar to those of osteoarthritis and may cover 
nonpharmacological methods such as physical therapy, local heat and/or acupuncture, in 
combination with pharmacological therapy, such as immediate short-term administration of 
NSAIDs, either systemically or topically [1, 3, 62, 63].
Besides arthralgia-type symptoms, breast cancer survivors may also progress fibrosis, rotator 
cuff pathology and distorted body habits, thereby leads to pain, limited range of motion and 
malfunctions in daily life, which are considered to be consequences of loco-regional treatment 
with surgery, with or without radiation therapy. Axillary web syndrome is the most extreme 
presentation of these symptoms. Physical and massage therapists are of great value as they 
are able to provide symptom relief by administering an intense regimen of massage, stretch-
ing and exercises that minimizes the need for surgical therapy. Physical therapy, including 
stretching and other exercises, has been reported to be efficient for managing postsurgical 
musculoskeletal symptoms. Recent reports from the hormones and physical exercise trial, a 
prospective cohort study, revealed that contribution in an intensive exercise regimen resulted 
in a 20% reduction in aromatase inhibitor-related pain. So far, only acupuncture and physi-
cal exercise have been reveled statistically significant improvement in aromatase inhibitor-
related symptoms. Additionally psychological support may help patients cope with pain and 
can also be helpful [1, 3, 62, 63].
6.5. Infertility, sexual dysfunction and urinary complaints
Infertility as a consequence of chemotherapeutics is a potential enduring deleterious effects 
faced by younger breast cancer survivors (younger than age 45 years). More than half of 
breast cancer survivors, especially those on adjuvant endocrine therapy suffer from sexual 
dysfunction [1, 3, 64–68] and urinary symptoms [1, 69]. Sexual dysfunction may be caused 
due to vaginal atrophy, diminished libido or feeling of pain during intercourse [1, 3]. Changes 
in libido have multiple causes, including mood disorder, pain, fatigue, estrogen deprivation 
and issues in relationship [1, 3]. Sexual issues can be partially subsided by using non-hor-
monal approaches i.e. by using moisturizers, lubricants, vitamin E and low doses of topical 
estrogens [1, 3]. Pelvic floor muscles exercises, gynecologic, vaginal dilatational measures and 
psychological care are also very helpful [1, 3]. Treatment with aromatase inhibitors usually 
cause vaginal dryness, menopausal symptoms, and loss of sexual desire [1, 3]. Radiation ther-
apy can often cause skin fibrosis, loss of sexual sensitivity of the skin, and, uncommonly, car-
diac and respiratory damage, all of which negatively impacts on sexual desire and response 
[1, 3, 70]. It is important to counsel patients concerning possible sexual dysfunction remedies, 
including treatments for vaginal dryness [1, 3]. Nonhormonal, water-based lubricants and 
moisturizers remain the primary treatment [1, 3, 71]. Silicone based products or glycerin-
based products also show very good results [3]. Hormonal therapies, such as a low-dose 
estrogen vaginal tablets or an estradiol vaginal ring, may be recommended for vaginal dry-
ness because of urogenital atrophy, although better results are shown approximately after 
6–12 week treatment [1, 3, 71, 72]. Urinary issues include overactive bladder with urgency 
with and without incontinence [1, 3]. Urinary complications can usually be reduced by pelvic 
floor muscle exercises, topical estrogen and, in some cases, by consulting a urogynecologist 
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[1, 3]. It is recommended that primary care clinicians should refer survivors of child bearing 
age who experience infertility to a specialist reproductive endocrinologist [1]. Infertility as a 
result of breast cancer treatment is a potential long-term side effect faced by younger breast 
cancer survivors. Infertility can have a profound impact on a survivor’s physical and social 
character [1, 3]. Chemotherapy can be gonadotoxic, leading to reduced fertility or early meno-
pause secondary to premature ovarian failure [1, 3, 73]. Many of the most frequently used 
chemotherapy agents in the treatment of breast cancer (e.g., alkylating agents and taxanes) 
are also those that most often lead to premature ovarian failure [1, 3, 74]. The incidence of 
chemotherapy-related amenorrhea has shown to be increased with age due the reason that 
the female ovarian reserve is nonrenewable and usually diminishes steadily with age [1, 3]. 
Primary care clinicians should involve the medical oncologist in any discussion related to the 
time for pregnancy after breast cancer treatment completion [1, 3]. Premenopausal women 
who desire pregnancy and are having difficulty conceiving for 6 months or more should be 
referred to a fertility specialist [1, 3]. Timely referral is crucial because of the rapid loss of 
ovarian reserve in these women [1, 3].
6.6. Management of bone health
It is estimated that osteoporosis affects one in every three postmenopausal women, with a 
40% lifetime risk of fracture and approximately 21% risk of 1-year mortality after hip fracture 
[3, 75]. Breast cancer survivors are at very high risk of bone loss due to chemotoxic effects on 
the bones, due to treatment induced hypogonadism, due to supportive steroid therapies and 
due to vitamin D deficiency [3, 69]. Simple measures, such as weight-bearing exercises, avoid-
ing of consumption of nicotine/alcohol and an adequate intake of calcium and vitamin D 
(600 mg/400 IU twice daily), are very essential for fracture risk reduction [1]. Breast cancer 
survivors should be monitored by dual-energy X-ray absorptiometry scans every 2 years [3]. 
Postmenopausal women treated with aromatase inhibitors are at increased risk of osteopo-
rosis and should have periodic dual-energy X-ray absorptiometry scans [3]. All postmeno-
pausal women or premenopausal women which are under GnRH agonist induced ovarian 
suppression therapy are at higher risk for developing osteoporosis and should be screened 
for postmenopausal osteoporosis diagnosis and treatment [1, 3]. In addition to lifestyle and 
nutritional interventions, pharmacologic options should be considered in patients, which are 
at high risk for bone loss [1, 3]. Bisphosphonates or denosumab can prevent bone loss and are 
good and established treatment options for osteoporosis [1, 3, 76, 77]. However, these drugs 
do have side effects and risks, so that the risk versus benefit must considered in a careful man-
ner [3]. Estrogen receptor modulators raloxifene and tamoxifen could also be used because of 
their antiresorptive nature.
6.7. Obesity concerns after treatment
About 62% of breast cancer survivors are overweight, of which 30% are classified as obese [2, 3]. 
Various research studies have presented obesity as a risk factor for postoperative complica-
tions, risk of recurrence, development of diabetes, and other issues [78]. Conversely, weight 
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loss subsides symptoms and improves QoL. Weight gain during breast cancer treatment is 
a serious problem [78]. Breast cancer survivors should avoid inactivity and return as soon 
as possible to normal activities after surgery and therapy [79]. American Society of Clinical 
Oncology (ASCO) has issued a statement that guides oncologists to counsel their patients 
about the benefits a healthy weight [80]. Primary care clinicians should also counsel cancer 
survivors to achieve or maintain a healthy weight as well as counsel survivors, to limit con-
sumption of high calorie foods, beverages, to increase physical activity and maintain healthy 
weight [1, 3]. Various research studies have shown that heavier survivors are more likely to 
die of cancer due to recurrence [3, 81]. Various suggestions and diet charts for getting back 
to healthy weight in breast cancer survivors have been recommended. E.g. eating at least 2 
cups of vegetables and fruits, more usage of whole grain foods like brown rice, less intake of 
saturated fats, preference of chicken and fish over red meat and moderate aerobic exercise of 
150 min per week has shown to reduce and subside the complications associated with breast 
cancer treatment [81].
6.8. Cardiovascular issues in breast cancer survivors
Breast cancer survivors are at increased risk of cardiovascular disease and the collective 
incidence rate is 33% [82] Breast cancer patients after treatment experience cardiotoxicity 
and it may also lead to cardiac issues like cardiomyopathy, thrombosis, pericardial dis-
ease and arrhythmias [82]. It is important to control and assess cardiovascular risk factors 
including weight, physical fitness, lipid profile and glucose tolerance [83]. A dietitian, psy-
chologist and personal trainer may help facilitate these efforts [3]. It is recommended that 
primary care clinicians should monitor lipid levels, provide cardiovascular monitoring and 
should also educate breast cancer survivors on healthy lifestyle modifications, potential 
cardiac risk factors [3]. Radiation, chemotherapy, and endocrine therapy with aromatase 
inhibitors have been associated with an increased risk of cardiovascular disease in patients 
with breast cancer [84]. The risk of heart disease increases in postmenopausal women, as 
endogenous estrogens in younger women contribute to the low prevalence of cardiovascu-
lar disease in that population [3]. Various studies have shown that breast cancer patients 
who experience treatment-related early menopause are at higher risk for development of 
heart disease [3]. The chemotherapeutic agents epirubicin and doxorubicin are associated 
with an increased risk of cardiomyopathy [85]. Similarly, trastuzumab is associated with an 
increased risk of cardiac dysfunction, most notably when taken together with anthracycline 
[2, 3, 85]. Aromatase inhibitors are known to raise cholesterol levels and the increase the risk 
of diabetes in breast cancer patients after or during treatment [3]. Excessive weight gain may 
lead to hypertension and insulin resistance, which further elevate the risk of cardiovascular 
disease [3]. Primary care clinicians and physicians should monitor lipid levels as well as 
monitor cardiovascular changes in cancer patients after treatment [3]. It is very essential to 
educate breast cancer survivors about daily lifestyle modifications, like smoking cessation, 
diet, and exercise that may be helpful in reducing severity and risks of cardiotoxicity [3]. 
Patients should be advised to be aware of the potential cardiotoxicity risk and also advised 
to report symptoms such as shortness of breath or fatigue to their health care provider [3].
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6.9. Lymphedema associated with breast cancer treatment
About 40% women breast survivors face a very higher risk of developing lymphedema 
[1, 3, 86]. Breast cancer related lymphedema results from obstruction of the lymphatic system 
due to removal of lymph nodes and tissue damages caused by radiotherapy [87]. Survivors 
personal habits like obesity and overweight can increase the chances of lymphedema [88]. 
Lymphedema has associated psychosocial problems that hamper day to day lives of breast 
cancer survivors [89]. Infections can trigger and worsen and the symptoms of lymphedema, 
so it is important to have good personal hygiene in order to reduce the risk of infection [3]. 
All patients in which lymphedema has developed should be referred to a physical or occu-
pational therapist or to lymphedema specialists [3]. Management of lymphedema remains 
a major challenge for patients and health care professionals [3]. Routine check-ups for 
lymphedema management, physical therapy, use of bandages, special lotions and frequent 
infections creates a huge financial burden not only to breast cancer survivors but also to the 
health care system [86]. Breast cancer-related lymphedema can occur in shoulders, breast, 
and thoracic area [86]. Treatments include pharmacological therapy and adjuvant therapies 
[3, 86]. Drugs included in the pharmacological management of lymphedema are benzopy-
rones, flavonoids, diuretics, hyaluronidase and selenium [86]. Surgical treatment for lymph-
edema in breast cancer survivors included lympholymphatic anastomoses, debulking and 
liposuction [3, 86]. Chronic lymphedema in breast cancer survivors sometimes lead to for-
mation of excess subcutaneous adipose tissue which can be removed by liposuction [86]. 
Liposuction increases the blood flow in skin capillaries without damaging already com-
promised lymph transport capacity in breast cancer survivors with lymphedema [1, 3, 86].
7. Strategies to improve breast cancer survivorship symptom care
7.1. Survivorship care plan
There has undoubtedly been a call from all over the globe to stress on the importance of largely 
on cancer survivorship and care. In recent past, first cancer survivorship symposium was held 
by ASCO, and highlights the crucial issues faced by cancer survivors and patients with numer-
ous cancers following treatment. Survivorship care strategies are recommended as crucial tool 
to assist communication and distribution of responsibility during the course of transition from 
active therapeutics to survivorship care. This care plan directs recommendations for the type and 
timing of follow-up imaging, laboratory tests, and other office visits. In addition cancer survival 
plan should incorporate necessary information regarding the deleterious effects of chemotherapy 
and what to watch for specifically based on the type of cancer and treatment received. Ideally, the 
oncology team should also work with the patient to develop an individualized cancer survivor-
ship care plan for breast cancer survivors. A brief outline of a patient’s diagnosis and treatment 
received should be presented by the oncologist team when a patient with breast cancer transitions 
care to other providers; a treatment outline should explain the type and stage/side of the cancer, 
type of surgery, the name of the chemotherapy/hormones/biologics and collective doses of che-
motherapy, and the types and collective doses of radiation therapy, together with the fields and 
extent of the radiation. However, the field of oncology in context with cancer survivorship and care 
plan is mostly struggling with how to excellently meet this recommendation and in categorize the 
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specific benefits of such care plans. Various tools and strategies to assist the creation and distribu-
tion of these care plans are being actively considered for all tumor sites, including breast cancer. 
Currently, challenges in workflow and tools make this difficult, but the field is working toward 
a sustainable solution. Patients can start the building of a cancer survivorship care plan course 
on the ASCO website (cancer.net/survivorship/follow-care-after-cancer-treatment/asco-cancer-
treatment-and-survivorship-care-plans; at journeyforward.org/or livestrongcareplan.org/).
8. Conclusion and future perspective
Despite the increasing number and longevity of breast cancer survivors the symptomology 
associated to therapeutics can be burdensome, multifaceted and long lasting and usually 
undertreated. Recent data suggest that management symptomology of these survivors could 
improvement of QoL, while evidence about its ability to reduce healthcare utilization is scarce. 
Cancer survivorship programmes help breast cancer survivors organize and remember their 
appointments. Communication and cooperation among providers and survivors are criti-
cal in the management and survivorship of breast cancer patients after treatment. Oncology 
teams all are working to develop a cancer survivorship care plan for breast cancer survivors. 
This care plan should guide survivors about the future laboratory tests, cardiovascular dis-
eases, musculoskeletal issues, psychosocial issues, and other issues from which they usually 
suffer after treatment. The care plan should include information on the risk for late effects of 
treatment. To summarize, cancer survivorship care is need of a hour to allow better care for a 
larger number of breast cancer survivors in a financially sustainable manner.
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